The Effect of Fda Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts
Year of publication: |
2013
|
---|---|
Authors: | Conti, Rena |
Other Persons: | Huskamp, Haiden (contributor) ; Berndt, Ernst R. (contributor) |
Publisher: |
[2013]: [S.l.] : SSRN |
Subject: | Pharmaindustrie | Pharmaceutical industry | Arzneimittel | Pharmaceuticals | Aufsichtsbehörde | Regulatory agency | Produktqualität | Product quality | Gesundheitswesen | Health care system |
Extent: | 1 Online-Ressource (27 p) |
---|---|
Series: | NBER Working Paper ; No. w17528 |
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments October 2011 erstellt |
Source: | ECONIS - Online Catalogue of the ZBW |
-
The effect of FDA advisories on branded pharmaceutical firms' valuations and promotion efforts
Conti, Rena M., (2011)
-
The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts
Conti, Rena M., (2011)
-
Perverse incentives in the medicare prescription drug benefit
McAdams, David, (2006)
- More ...
-
The effect of FDA advisories on branded pharmaceutical firms' valuations and promotion efforts
Conti, Rena M., (2011)
-
The Geography of Prescription Pharmaceuticals Supplied to the U.S : Levels, Trends and Implications
Kaygisiz, Neriman Beste, (2019)
-
Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001-2007
Conti, Rena, (2014)
- More ...